Expression of forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores

Modern Pathology

Volumn 23, Issue 2, 2010, Pages 270-275

  Ademuyiwa, Foluso O ^a   Thorat, Mangesh A ^a   Jain, Rohit K ^a   Nakshatri, Harikrishna ^a   Badve, Sunil ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

FOXA1 expression; GATA3 expression; Luminal A type breast cancer marker; Oncotype DX

Indexed keywords

ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR GATA 3;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOTYPE DX 21 ASSAY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SCORING SYSTEM; TUMOR GENE; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY, MOLECULAR; PROGNOSIS; REAGENT KITS, DIAGNOSTIC; TUMOR MARKERS, BIOLOGICAL;

EID: 76349121790     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.172     Document Type: Article

References (27)

1. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351: 2817-2826.
2. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
3. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-569.
4. Ignatiadis M, Sotiriou C. Understanding the molecular basis of histologic grade. Pathobiology 2008;75: 104-111.
5. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007;25:1239-1246.
6. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:607-616.
7. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
8. Ross DT, Kim CY, Tang G, et al. Chemosensitivity and stratification by a five monoclonal antibody immuno-histochemistry test in the NSABP B14 and B20 trials. Clin Cancer Res 2008;14:6602-6609.
9. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005;102:3738-3743.
10. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
11. Eeckhoute J, Keeton EK, Lupien M, et al. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res 2007;67:6477-6483.
12. Kouros-Mehr H, Slorach EM, Sternlicht MD, et al. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 2006;127: 1041-1055.
13. Thorat MA, Marchio C, Morimiya A, et al. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol 2008;61:327-332.
14. Carroll JS, Brown M. Estrogen receptor target gene: an evolving concept. Mol Endocrinol 2006;20:1707-1714.
15. Laganiere J, Deblois G, Lefebvre C, et al. From the Cover: location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA 2005;102:11651-11656.
16. Asselin-Labat ML, Sutherland KD, Barker H, et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 2007;9:201-209.
17. Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin Cancer Res 2007;13:4415-4421.
18. Clarke RB, Howell A, Potten CS, et al. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997;57:4987-4991.
19. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
20. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
21. Carlson RW, McCormick B. Update: NCCN breast cancer Clinical Practice Guidelines. J Natl Compr Cancer Netw 2005;3:S7-S11.
22. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-1583. (Pubitemid 41511089)
23. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-991.
24. Wolf I, Ben-Baruch N, Shapira-Frommer R, et al. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study. Cancer 2008;112:731-736.
25. Flanagan MB, Dabbs DJ, Brufsky AM, et al. Histo-pathologic variables predict Oncotype DX recurrence score. Mod Pathol 2008;21:1255-1261.
26. Henry LR, Stojadinovic A, Swain SM, et al. The influence of a Gene expression profile on breast cancer decisions. J Surg Oncol 2009;99:319-323.
27. Oratz R, Paul D, Cohn AL, et al. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 2007;3:182-188.